This review aims to summarize the recent developments of ADP-ribosylation in DNA repair, focusing on the crosstalk of ADP-ribosylation with additional protein post-translational modifications and the progress of PARP inhibitors in cancer therapy. The gene discussed is PARP1; the disease is cancer.